- Home
- BIIB vs NTRS Comparison
BIIB vs NTRS Comparison
Compare BIIB & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTRS
- Stock Information
- Founded
- BIIB 1978
- NTRS 1889
- Country
- BIIB United States
- NTRS United States
- Employees
- BIIB N/A
- NTRS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTRS Major Banks
- Sector
- BIIB Health Care
- NTRS Finance
- Exchange
- BIIB Nasdaq
- NTRS Nasdaq
- Market Cap
- BIIB 18.7B
- NTRS 25.0B
- IPO Year
- BIIB 1991
- NTRS N/A
- Fundamental
- Price
- BIIB $143.99
- NTRS $129.04
- Analyst Decision
- BIIB Buy
- NTRS Hold
- Analyst Count
- BIIB 27
- NTRS 14
- Target Price
- BIIB $188.09
- NTRS $117.08
- AVG Volume (30 Days)
- BIIB 1.5M
- NTRS 940.0K
- Earning Date
- BIIB 10-29-2025
- NTRS 10-22-2025
- Dividend Yield
- BIIB N/A
- NTRS 2.44%
- EPS Growth
- BIIB 31.67
- NTRS 17.17
- EPS
- BIIB 10.45
- NTRS 8.52
- Revenue
- BIIB $9,997,000,000.00
- NTRS $7,851,000,000.00
- Revenue This Year
- BIIB $2.00
- NTRS N/A
- Revenue Next Year
- BIIB N/A
- NTRS $3.66
- P/E Ratio
- BIIB $13.78
- NTRS $15.38
- Revenue Growth
- BIIB 3.36
- NTRS 3.17
- 52 Week Low
- BIIB $110.04
- NTRS $81.62
- 52 Week High
- BIIB $204.18
- NTRS $133.00
- Technical
- Relative Strength Index (RSI)
- BIIB 58.91
- NTRS 51.78
- Support Level
- BIIB $141.12
- NTRS $125.98
- Resistance Level
- BIIB $150.28
- NTRS $131.55
- Average True Range (ATR)
- BIIB 4.60
- NTRS 2.43
- MACD
- BIIB 0.32
- NTRS -0.16
- Stochastic Oscillator
- BIIB 66.47
- NTRS 51.35
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NTRS Northern Trust Corporation
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2024, Northern Trust had assets under custody or administration of $16.8 trillion and assets under management of $1.6 trillion.